KYMR
HEALTHCAREKymera Therapeutics Inc
$86.26+3.55 (+4.29%)PRE
Live · NASDAQ · May 8, Close
AI Insight
What's Moving KYMR Today?
No stock-specific AI insight has been generated for KYMR yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$28.06$103.00
$86.26
Fundamentals
Market Cap$7.1B
P/E Ratio—
EPS$-3.58
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume427K
Avg Volume (10D)—
Shares Outstanding82.3M
KYMR News
20 articles- How The Kymera Therapeutics (KYMR) Story Is Shifting Around KT-621 And Degrader PotentialYahoo Finance·May 7, 2026
- AMD upgraded, Reddit downgraded: Wall Street's top analyst callsYahoo Finance·May 6, 2026
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, American Eagle Outfitters, GlobalFoundries, IAC, Merck, Palantir Technologies, Reddit, and More247 Wall St·May 6, 2026
- Kymera Therapeutics to Participate in Upcoming May Investor ConferencesYahoo Finance·May 6, 2026
- Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease WeekYahoo Finance·May 5, 2026
- Jeito Capital Bolsters Its Leadership Team With the Appointment of Elaine Caughey, MBA, as Partner, Business Development and Investor Relations, and Sarah Shackelton, MPA, as Partner, TalentYahoo Finance·May 5, 2026
- Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesYahoo Finance·May 4, 2026
- KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD CollaborationYahoo Finance·May 1, 2026
- Kymera Therapeutics Q1 Earnings Call HighlightsMarketbeat·Apr 30, 2026
- Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Apr 30, 2026
- Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business UpdateYahoo Finance·Apr 30, 2026
- Wave Life Sciences (WVE) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·Apr 28, 2026
- Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio StrategyYahoo Finance·Apr 27, 2026
- A Look At Kymera Therapeutics (KYMR) Valuation After Fast Track News And Gilead Collaboration ProgressYahoo Finance·Apr 26, 2026
- FDA Grants Fast Track Designation to Kymera Therapeutics, Inc. (KYMR)’s KT-621 for Eosinophilic AsthmaYahoo Finance·Apr 24, 2026
- Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026GlobeNewswire Inc.·Apr 23, 2026
- KYMR Stock Up as FDA Grants Fast Track Designation to Asthma DrugYahoo Finance·Apr 14, 2026
- Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe AsthmaYahoo Finance·Apr 13, 2026
- Gilead’s Tubulis Deal Recasts Oncology Ambitions And HIV Reliance RisksYahoo Finance·Apr 11, 2026
- KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200Yahoo Finance·Apr 10, 2026
All 20 articles loaded
Price Data
Open$84.08
Previous Close$82.71
Day High$86.30
Day Low$83.85
52 Week High$103.00
52 Week Low$28.06
52-Week Range
$28.06$103.00
$86.26
Fundamentals
Market Cap$7.1B
P/E Ratio—
EPS$-3.58
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume427K
Avg Volume (10D)—
Shares Outstanding82.3M
About Kymera Therapeutics Inc
Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down disease-causing proteins by harnessing the body's own natural protein breakdown system. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—